A Study in Infants With RSV LRTI to Evaluate RV521
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a multicentre, 3-part study to evaluate safety, tolerability, PK, PD, and antiviral
effect of single and multiple dosing of RV521 in infants hospitalised due to Respiratory
Syncytial Virus (RSV) lower respiratory tract infection (LRTI). Due to the adaptive study
design, the number of enrolled subjects may vary depending on the obtained PK and safety
profiles.